465 related articles for article (PubMed ID: 12525516)
1. Phase II trial of procarbazine, lomustine, and vincristine as initial therapy for patients with low-grade oligodendroglioma or oligoastrocytoma: efficacy and associations with chromosomal abnormalities.
Buckner JC; Gesme D; O'Fallon JR; Hammack JE; Stafford S; Brown PD; Hawkins R; Scheithauer BW; Erickson BJ; Levitt R; Shaw EG; Jenkins R
J Clin Oncol; 2003 Jan; 21(2):251-5. PubMed ID: 12525516
[TBL] [Abstract][Full Text] [Related]
2. Successful treatment of low-grade oligodendroglial tumors with a chemotherapy regimen of procarbazine, lomustine, and vincristine.
Stege EM; Kros JM; de Bruin HG; Enting RH; van Heuvel I; Looijenga LH; van der Rijt CD; Smitt PA; van den Bent MJ
Cancer; 2005 Feb; 103(4):802-9. PubMed ID: 15637687
[TBL] [Abstract][Full Text] [Related]
3. Phase III trial of chemotherapy plus radiotherapy compared with radiotherapy alone for pure and mixed anaplastic oligodendroglioma: Intergroup Radiation Therapy Oncology Group Trial 9402.
; Cairncross G; Berkey B; Shaw E; Jenkins R; Scheithauer B; Brachman D; Buckner J; Fink K; Souhami L; Laperierre N; Mehta M; Curran W
J Clin Oncol; 2006 Jun; 24(18):2707-14. PubMed ID: 16782910
[TBL] [Abstract][Full Text] [Related]
4. Adjuvant procarbazine, lomustine, and vincristine improves progression-free survival but not overall survival in newly diagnosed anaplastic oligodendrogliomas and oligoastrocytomas: a randomized European Organisation for Research and Treatment of Cancer phase III trial.
van den Bent MJ; Carpentier AF; Brandes AA; Sanson M; Taphoorn MJ; Bernsen HJ; Frenay M; Tijssen CC; Grisold W; Sipos L; Haaxma-Reiche H; Kros JM; van Kouwenhoven MC; Vecht CJ; Allgeier A; Lacombe D; Gorlia T
J Clin Oncol; 2006 Jun; 24(18):2715-22. PubMed ID: 16782911
[TBL] [Abstract][Full Text] [Related]
5. Chromosomal anomalies in oligodendroglial tumors are correlated with clinical features.
van den Bent MJ; Looijenga LH; Langenberg K; Dinjens W; Graveland W; Uytdewilligen L; Sillevis Smitt PA; Jenkins RB; Kros JM
Cancer; 2003 Mar; 97(5):1276-84. PubMed ID: 12599236
[TBL] [Abstract][Full Text] [Related]
6. Molecular analysis of anaplastic oligodendroglial tumors in a prospective randomized study: A report from EORTC study 26951.
Kouwenhoven MC; Gorlia T; Kros JM; Ibdaih A; Brandes AA; Bromberg JE; Mokhtari K; van Duinen SG; Teepen JL; Wesseling P; Vandenbos F; Grisold W; Sipos L; Mirimanoff R; Vecht CJ; Allgeier A; Lacombe D; van den Bent MJ
Neuro Oncol; 2009 Dec; 11(6):737-46. PubMed ID: 19224764
[TBL] [Abstract][Full Text] [Related]
7. PC or PCV, That Is the Question: Primary Anaplastic Oligodendroglial Tumors Treated with Procarbazine and CCNU With and Without Vincristine.
Webre C; Shonka N; Smith L; Liu D; De Groot J
Anticancer Res; 2015 Oct; 35(10):5467-72. PubMed ID: 26408710
[TBL] [Abstract][Full Text] [Related]
8. Genetic and metabolic predictors of chemosensitivity in oligodendroglial neoplasms.
Walker C; Haylock B; Husband D; Joyce KA; Fildes D; Jenkinson MD; Smith T; Broome J; Kopitzki K; du Plessis DG; Prosser J; Vinjamuri S; Warnke PC
Br J Cancer; 2006 Nov; 95(10):1424-31. PubMed ID: 17031404
[TBL] [Abstract][Full Text] [Related]
9. How to use molecular markers when caring for a patient with brain cancer: 1P/19Q as a predictive and prognostic marker in the neuro-oncology clinic.
van den Bent MJ
Am Soc Clin Oncol Educ Book; 2013; ():114-6. PubMed ID: 23714473
[TBL] [Abstract][Full Text] [Related]
10. Anaplastic oligodendroglioma and oligoastrocytoma.
van den Bent MJ
Neurol Clin; 2007 Nov; 25(4):1089-109, ix-x. PubMed ID: 17964027
[TBL] [Abstract][Full Text] [Related]
11. Phase II study of accelerated fractionation radiation therapy with carboplatin followed by PCV chemotherapy for the treatment of anaplastic gliomas.
Levin VA; Yung WK; Bruner J; Kyritsis A; Leeds N; Gleason MJ; Hess KR; Meyers CA; Ictech SA; Chang E; Maor MH
Int J Radiat Oncol Biol Phys; 2002 May; 53(1):58-66. PubMed ID: 12007942
[TBL] [Abstract][Full Text] [Related]
12. Procarbazine, lomustine, and vincristine (PCV) chemotherapy for grade III and grade IV oligoastrocytomas.
Kim L; Hochberg FH; Thornton AF; Harsh GR; Patel H; Finkelstein D; Louis DN
J Neurosurg; 1996 Oct; 85(4):602-7. PubMed ID: 8814163
[TBL] [Abstract][Full Text] [Related]
13. New clinical, pathological and molecular prognostic models and calculators in patients with locally diagnosed anaplastic oligodendroglioma or oligoastrocytoma. A prognostic factor analysis of European Organisation for Research and Treatment of Cancer Brain Tumour Group Study 26951.
Gorlia T; Delattre JY; Brandes AA; Kros JM; Taphoorn MJ; Kouwenhoven MC; Bernsen HJ; Frénay M; Tijssen CC; Lacombe D; van den Bent MJ
Eur J Cancer; 2013 Nov; 49(16):3477-85. PubMed ID: 23896377
[TBL] [Abstract][Full Text] [Related]
14. MGMT promoter methylation is prognostic but not predictive for outcome to adjuvant PCV chemotherapy in anaplastic oligodendroglial tumors: a report from EORTC Brain Tumor Group Study 26951.
van den Bent MJ; Dubbink HJ; Sanson M; van der Lee-Haarloo CR; Hegi M; Jeuken JW; Ibdaih A; Brandes AA; Taphoorn MJ; Frenay M; Lacombe D; Gorlia T; Dinjens WN; Kros JM
J Clin Oncol; 2009 Dec; 27(35):5881-6. PubMed ID: 19901104
[TBL] [Abstract][Full Text] [Related]
15. Alterations of chromosome arms 1p and 19q as predictors of survival in oligodendrogliomas, astrocytomas, and mixed oligoastrocytomas.
Smith JS; Perry A; Borell TJ; Lee HK; O'Fallon J; Hosek SM; Kimmel D; Yates A; Burger PC; Scheithauer BW; Jenkins RB
J Clin Oncol; 2000 Feb; 18(3):636-45. PubMed ID: 10653879
[TBL] [Abstract][Full Text] [Related]
16. Adjuvant procarbazine, lomustine, and vincristine chemotherapy in newly diagnosed anaplastic oligodendroglioma: long-term follow-up of EORTC brain tumor group study 26951.
van den Bent MJ; Brandes AA; Taphoorn MJ; Kros JM; Kouwenhoven MC; Delattre JY; Bernsen HJ; Frenay M; Tijssen CC; Grisold W; Sipos L; Enting RH; French PJ; Dinjens WN; Vecht CJ; Allgeier A; Lacombe D; Gorlia T; Hoang-Xuan K
J Clin Oncol; 2013 Jan; 31(3):344-50. PubMed ID: 23071237
[TBL] [Abstract][Full Text] [Related]
17. Improvement of functional outcome for patients with newly diagnosed grade 2 or 3 gliomas with co-deletion of 1p/19q - IMPROVE CODEL: the NOA-18 trial.
Wick A; Sander A; Koch M; Bendszus M; Combs S; Haut T; Dormann A; Walter S; Pertz M; Merkle-Lock J; Selkrig N; Limprecht R; Baumann L; Kieser M; Sahm F; Schlegel U; Winkler F; Platten M; Wick W; Kessler T
BMC Cancer; 2022 Jun; 22(1):645. PubMed ID: 35692047
[TBL] [Abstract][Full Text] [Related]
18. Radiation and chemotherapy for high-risk lower grade gliomas: Choosing between temozolomide and PCV.
McDuff SGR; Dietrich J; Atkins KM; Oh KS; Loeffler JS; Shih HA
Cancer Med; 2020 Jan; 9(1):3-11. PubMed ID: 31701682
[TBL] [Abstract][Full Text] [Related]
19. Treatment of large low-grade oligodendroglial tumors with upfront procarbazine, lomustine, and vincristine chemotherapy with long follow-up: a retrospective cohort study with growth kinetics.
Taal W; van der Rijt CC; Dinjens WN; Sillevis Smitt PA; Wertenbroek AA; Bromberg JE; van Heuvel I; Kros JM; van den Bent MJ
J Neurooncol; 2015 Jan; 121(2):365-72. PubMed ID: 25344884
[TBL] [Abstract][Full Text] [Related]
20. Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas.
Cairncross JG; Ueki K; Zlatescu MC; Lisle DK; Finkelstein DM; Hammond RR; Silver JS; Stark PC; Macdonald DR; Ino Y; Ramsay DA; Louis DN
J Natl Cancer Inst; 1998 Oct; 90(19):1473-9. PubMed ID: 9776413
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
